Sun Pharmaceutical Industries Limited has informed the Exchange about Financial Results and Recommendation of Dividend for FY 2025-26
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma reported audited standalone revenue of ₹2,07,546 million for FY2025-26, down ~8% from ₹2,29,774 million in the prior year. Standalone PAT fell to ₹26,234 million from ₹42,281 million — a ~38% decline — partly driven by exceptional charges of ₹5,463 million, which included impairment of the SCD-044 drug candidate (₹1,515 million intangible asset + ₹1,361 million related R&D costs) and ₹2,587 million incremental cost from new Indian labour codes. EBITDA margin compressed from ~31% to ~28%. The company also adopted the new Section 115BAA concessional tax regime effective FY2026-27. Auditors issued an unmodified (clean) opinion. The Board recommended a final dividend of ₹5 per share, in addition to the ₹11 interim dividend already paid, totalling ₹16 per share.
Revenue decline and sharp PAT contraction signal pressure on profitability, though the exceptional items are largely non-cash or one-time in nature. The clean audit opinion and unchanged total dividend (₹16/share) provide some comfort. Investors should watch for normalised earnings recovery in FY2026-27 given the new tax regime tailwind.